Evidence map›Paper›PMID 28532429›Full record

ArticleBMC cancer2017

Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.

Sasagu Kurozumi, Hiroshi Matsumoto, Yuji Hayashi, Katsunori Tozuka, Kenichi Inoue, Jun Horiguchi, Izumi Takeyoshi, Tetsunari Oyama, Masafumi Kurosumi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 69 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sasagu KurozumiDivision of Breast Surgery, Saitama Cancer Center, Saitama, Japan.
Hiroshi MatsumotoDivision of Breast Surgery, Saitama Cancer Center, Saitama, Japan.
Yuji HayashiDivision of Breast Surgery, Saitama Cancer Center, Saitama, Japan.
Katsunori TozukaDivision of Breast Surgery, Saitama Cancer Center, Saitama, Japan.
Kenichi InoueDivision of Breast Oncology, Saitama Cancer Center, Saitama, Japan.
Jun HoriguchiDepartment of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Gunma, Japan.
Izumi TakeyoshiDepartment of Thoracic and Visceral Organ Surgery, Gunma University Graduate School of Medicine, Gunma, Japan.
Tetsunari OyamaDepartment of Diagnostic Pathology, Gunma University Graduate School of Medicine, Gunma, Japan.
Masafumi KurosumiDepartment of Pathology, Saitama Cancer Center, 780 Komuro, Ina-machi, Kitaadachi-gun, Saitama, 362-0806, Japan. mkurosumi@cancer-c.pref.saitama.jp.
Saitama Cancer Center · JPGunma University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Ki67 labeling index (LI) is regarded as a significant prognostic marker in ER-positive/HER2-negative breast cancer patients. The expression of PgR has recently been identified as another prognostic marker. In the present study, we investigated the prognostic utilities and most suitable cut-off values for Ki67 and PgR, and evaluated the relationship between Ki67 LI and PgR expression in ER-positive/HER2-negative breast cancer. PATIENTS AND

methodsIn the present study, 177 consecutive Japanese women with ER-positive/HER2-negative invasive carcinoma of no special type who were treated between 2000 and 2001 were enrolled. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were analyzed according to Ki67 LI and PgR expression, and significant cut-off values for selecting patients with a poor prognosis were evaluated.

resultsThe cut-off values for Ki67 LI as a prognostic marker plotted against P values showed bimodal peaks at 10% and 30%. Among the cut-off points examined for the PgR status, 20% PgR positivity was the most significant for predicting survival differences (RFS: P = 0.0003; CSS: P < 0.0001). A multivariate analysis showed that PgR (≥20%) was an independent prognostic marker (RFS: P = 0.0092; CSS: P = 0.00014). Furthermore, in the intermediate risk group with Ki67 LI of 10-30%, the low PgR <20% group had a markedly poorer prognosis for RFS and CSS (RFS: P < 0.0001; CSS: P < 0.0001).

conclusionsThe expression of PgR is a potent prognostic indicator for evaluating the long-term prognosis of ER-positive/HER2-negative breast cancer, and the most suitable cut-off value was found to be 20%. Furthermore, the PgR status is a powerful method for selecting patients with a poor prognosis among ER-positive/HER2-negative patients at intermediate risk, as assessed using Ki67 LI.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastErb-b2 Receptor Tyrosine KinasesFemaleHumansKaplan-Meier EstimateKi-67 AntigenMiddle AgedMultivariate AnalysisPrognosisProportional Hazards ModelsReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesKi-67 AntigenReceptors, EstrogenReceptors, ProgesteroneER-positive and HER2-negative breast cancerKi67 labeling indexProgesterone receptorPrognosis

Identifiers

PMID28532429
PMCPMC5441075
OpenAlexW2619639925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.